glp-1 and cancer risk GLP-1s in Oncology: Exploring Risks Potential Benefits Research Reveals Potential Risks of
Description
The lower use among people 65 and older is likely because Medicare doesnt cover prescriptions solely for weight loss, KFF says
de Mesquita YLL et al
Visceral Fat Redistribution Menopause often shifts fat storage from subcutaneous areas to visceral abdominal depots, even when total body weight remains stable
Microdosing may reduce some of the most common side effects of GLP-1 drugs, but it doesn't necessarily eliminate the medications' risks
Clinical trials show weight loss averaging 1522% of body weight over 68 weeks, far exceeding the effects of SGLT2 inhibitors alone
SGLT2 inhibitor as add-on antihyperglycemic therapy
